ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar


No votes yet
 
Related
Laboratorios Farmacéuticos ROVI, S.A. (ROVI) informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone...
2 min
16/02/2023
Madrid, 6th February, 2023 This Monday, the Romanian Minister of Health, Alexandru Rafila, visited the ROVI plant in Alcalá de Henares....
2 min
06/02/2023
Madrid: 28 of December 2022 The project entitled “Bioreactors and Biostains with Heparin for the Regeneration of Elastic Tissues (...
1 min
28/12/2022